FDA-Approved Synthetic THC Trials Show 21% Tic Reduction In Tourette Syndrome Patients

SciSparc Ltd. SPRC, a clinical-stage pharmaceutical company, reported a new Phase IIb trial of SCI-110, a proprietary THC-based medication for Tourette Syndrome (TS) treatment.

Global Collaboration for TS Advancements

Spanning across renowned institutions such as Yale University, Tel Aviv Sourasky Medical Center and Hannover Medical School, the trial operates under the regulations of the Food and Drug Administration, BfArM and Israeli Ministry of Health.

Addressing a significant gap in TS management, SCI-110 combines FDA-approved synthetic THC (Dronabinol) with palmitoylethanolamide to stimulate cannabinoid receptors in the central nervous system.

SCI-110: Trial Results

Designed for oral administration, SCI-110 aims for increased efficiency, reduced dosage and fewer side effects.

Targeting adults aged 18-65, the trial compares SCI-110 to a placebo using the Yale Global Tic Severity Scale.

Phase IIA results at Yale University showcased a promising 21% average tic reduction with nearly 40% experiencing over a 25% reduction. Notably, 12 out of 16 subjects opted for a 24-week extension, underscoring positive tolerability.

SciSparc's focus on cannabinoid pharmaceuticals extends to ongoing programs like SCI-160 for pain treatment and SCI-210 for ASD and status epilepticus.

The company reported the Phase IIb trial signals a breakthrough in TS management, offering hope for enhanced efficacy and safety in treating this neurobehavioral disorder.

Cannabinoid Pharmaceuticals

SciSparc focuses on cannabinoid pharmaceuticals. Its current drug development programs include SCI-110 for Tourette Syndrome and Alzheimer's, SCI-160 for pain, and SCI-210 for ASD and status epilepticus. The company also holds a controlling interest in a subsidiary selling hemp seed oil-based products via Amazon.

Photo by Google DeepMind on Unsplash.